ESTRO PT 2018

University of Florida Proton Therapy Institute

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer (status: open at UFPTI, opened multi-centric via PCG)

Phase I: Hypofractionated Proton Radiation Therapy with Concurrent Chemotherapy*

Arm 1: 60 CGE at 2.5 CGE/fraction for 24 fractions

Arm 2: 60 CGE at 3 CGE/fraction for 20 fractions

Arm 3: 60 CGE at 3.53 CGE/fraction for 17 fractions

Arm 4: 60 CGE at 4 CGE/fraction for 15 fractions

Phase II: Hypofractionated Proton Radiation Therapy with Concurrent Chemotherapy* based on the Maximum Dose Tolerated (MDT) of Phase I

*Chemotherapy is required Suggested regimen: concurrent weekly paclitaxel at 45 mg/m 2 and carboplatin at AUC 2 mg/min/ml. Optional adjuvant chemotherapy is acceptable .